Ianalumab在抗治疗性ITP中减少了出血和耗竭的B细胞,而林业发展局则批准对Wiskott-Aldrich综合症进行基因治疗。 Ianalumab reduced bleeding and depleted B cells in treatment-resistant ITP, while FDA approved gene therapy for Wiskott-Aldrich syndrome.

VAYHIT3试验显示,在2025年ASH时,Ayanalumab是BAFF针对单克隆抗体的一种单克隆抗体,它减少了初级免疫性血栓细胞的出血和B细胞的耗竭,为抗治疗性病人带来了希望。 At ASH 2025, the VAYHIT3 trial revealed that ianalumab, a BAFF-targeting monoclonal antibody, reduced bleeding and depleted B cells in primary immune thrombocytopenia, offering hope for treatment-resistant patients. 美国食品和药物管理局批准了Etuvetidigene autotemcel用于威斯科特-阿尔德里希综合征, The FDA approved etuvetidigene autotemcel for Wiskott-Aldrich syndrome, marking a gene therapy milestone. 其他突出成果包括bezuclastinib在非晚期全身性乳腺细胞瘤的生物标志物降低和GLP-1激动剂对心血管的益处. Other highlights included bezuclastinib’s biomarker reduction in non-advanced systemic mastocytosis and cardiovascular benefits from GLP-1 agonists.